GLP-1 and Brain Health: What the EVOKE Trial Failure Actually Tells Us
The EVOKE trials failed to show semaglutide slows Alzheimer's progression. Headlines called it a setback. But the full story is more nuanced—and more interesting. Real-world data still shows 40-70% reduced dementia risk in GLP-1 users. The lesson isn't that GLP-1s don't help the brain. It's that timing might be everything.